bioAffinity Technologies (BIAF) Consolidated Net Income (2021 - 2026)

bioAffinity Technologies (BIAF) has reported Consolidated Net Income for 6 consecutive years, with -$3.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Consolidated Net Income fell 36.47% year-over-year to -$3.6 million; the TTM figure through Mar 2026 stood at -$15.9 million (down 63.06% YoY), while the FY2025 annual figure was -$14.9 million, down 64.93% from the prior year.
• Consolidated Net Income retreated to -$3.6 million in Q1 2026 per BIAF's latest filing, from -$3.1 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$88052.0 in Q2 2022 and bottomed at -$5.1 million in Q3 2025.
• Historically, Consolidated Net Income has averaged -$2.6 million across 5 years, with a median of -$2.3 million in 2023.
• Annual changes were most pronounced in 2022 — Consolidated Net Income soared 69.97% — and 2023, when it slumped 1876.3%.
• bioAffinity Technologies' Consolidated Net Income stood at -$1.7 million in 2022, then tumbled by 41.72% to -$2.4 million in 2023, then retreated by 25.02% to -$3.0 million in 2024, then retreated by 5.75% to -$3.1 million in 2025, then slipped by 15.72% to -$3.6 million in 2026.
• Business Quant data shows BIAF's Consolidated Net Income at -$3.6 million in Q1 2026, -$3.1 million in Q4 2025, and -$5.1 million in Q3 2025.